We are analyzing https://link.springer.com/article/10.1186/1741-7015-11-43.

Title:
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | BMC Medicine
Description:
Background Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population. Methods This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg). The previously published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting plasma glucose (FPG), and weight. Results A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P <0.0001), and -0.78% (P <0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively. In addition, all dapagliflozin groups had sustained reductions from baseline in FPG (-1.07 to -1.47 mmol/l) and body weight (-1.10 to -1.74 kg) at 102 weeks, whereas increases were noted in placebo-treated patients for both of these outcomes. Events of hypoglycemia were rare and were not severe. Evidence suggestive of genital infection was reported in 11.7% to 14.6% of dapagliflozin patients and 5.1% of placebo patients, with one related discontinuation (dapagliflozin 5 mg). Evidence suggestive of urinary tract infection was reported in 8.0% to 13.3% of dapagliflozin patients and 8.0% of placebo patients, with one related discontinuation (dapagliflozin 2.5 mg). Conclusions Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone. Trial registration ClinicalTrials.gov: NCT00528879
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

dapagliflozin, patients, diabetes, week, placebo, article, type, baseline, metformin, weeks, study, hbac, pubmed, data, trial, table, rescue, glycemic, groups, google, scholar, treatment, group, extension, therapy, weight, control, cas, change, events, insulin, sglt, controlled, doubleblind, reported, bristolmyers, squibb, inadequately, randomized, longterm, care, list, fpg, period, compared, body, adverse, received, authors, access,

Topics {✒️}

sodium-glucose cotransporter-2 inhibitor active-controlled noninferiority trial pre-publication history long-term double-blind extension parc de l'alliance sodium-glucose cotransport inhibition undertaken ad-hoc consultancy β-cell function declines β-cell function superimposed sodium-glucose cotransporter 2 david yaw twum-barima drug-naïve japanese patients article download pdf received research support continued open-label metformin present long-term study received research grants induces dose-dependent glucosuria phase 3 trial long-term dapagliflozin therapy improved glycemic control open-label extensions full size image privacy choices/manage cookies placebo-controlled 102-week trial double-blind extension period adequate glycemic control renal proximal tubule glycemic control challenging improve glycemic control inadequate glycemic control 24-week phase 3 observation carried forward cardiovascular complications [17 treatment-related weight reduction β-cell function full access open-label metformin long-term efficacy dapagliflozin-treated patients remained fasting plasma glucose additional therapeutic option inadequate glycaemic control serum uric acid authors’ original file glucose-lowering effect diastolic blood pressure long-term extension biomed central long-term therapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
         description:Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population. This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg). The previously published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting plasma glucose (FPG), and weight. A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P <0.0001), and -0.78% (P <0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively. In addition, all dapagliflozin groups had sustained reductions from baseline in FPG (-1.07 to -1.47 mmol/l) and body weight (-1.10 to -1.74 kg) at 102 weeks, whereas increases were noted in placebo-treated patients for both of these outcomes. Events of hypoglycemia were rare and were not severe. Evidence suggestive of genital infection was reported in 11.7% to 14.6% of dapagliflozin patients and 5.1% of placebo patients, with one related discontinuation (dapagliflozin 5 mg). Evidence suggestive of urinary tract infection was reported in 8.0% to 13.3% of dapagliflozin patients and 8.0% of placebo patients, with one related discontinuation (dapagliflozin 2.5 mg). Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone. ClinicalTrials.gov: NCT00528879
         datePublished:2013-02-20T00:00:00Z
         dateModified:2013-02-20T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1741-7015-11-43
         keywords:
            Dapagliflozin
            metformin
            SGLT2
            sodium-glucose cotransporter 2
            glycemic control
            type 2 diabetes
            Medicine/Public Health
            general
            Biomedicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-43/MediaObjects/12916_2012_Article_704_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-43/MediaObjects/12916_2012_Article_704_Fig2_HTML.jpg
         isPartOf:
            name:BMC Medicine
            issn:
               1741-7015
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Clifford J Bailey
               affiliation:
                     name:Aston University
                     address:
                        name:Life and Health Sciences, Aston University, Birmingham, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jorge L Gross
               affiliation:
                     name:Universidade Federal do Rio Grande do Sul
                     address:
                        name:Endocrine Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Delphine Hennicken
               affiliation:
                     name:Bristol-Myers Squibb, Parc de l'Alliance
                     address:
                        name:Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Braine I'Alleud, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nayyar Iqbal
               affiliation:
                     name:Bristol-Myers Squibb
                     address:
                        name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Traci A Mansfield
               affiliation:
                     name:Bristol-Myers Squibb
                     address:
                        name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James F List
               affiliation:
                     name:Bristol-Myers Squibb
                     address:
                        name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
      description:Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population. This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg). The previously published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting plasma glucose (FPG), and weight. A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P <0.0001), and -0.78% (P <0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively. In addition, all dapagliflozin groups had sustained reductions from baseline in FPG (-1.07 to -1.47 mmol/l) and body weight (-1.10 to -1.74 kg) at 102 weeks, whereas increases were noted in placebo-treated patients for both of these outcomes. Events of hypoglycemia were rare and were not severe. Evidence suggestive of genital infection was reported in 11.7% to 14.6% of dapagliflozin patients and 5.1% of placebo patients, with one related discontinuation (dapagliflozin 5 mg). Evidence suggestive of urinary tract infection was reported in 8.0% to 13.3% of dapagliflozin patients and 8.0% of placebo patients, with one related discontinuation (dapagliflozin 2.5 mg). Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone. ClinicalTrials.gov: NCT00528879
      datePublished:2013-02-20T00:00:00Z
      dateModified:2013-02-20T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1741-7015-11-43
      keywords:
         Dapagliflozin
         metformin
         SGLT2
         sodium-glucose cotransporter 2
         glycemic control
         type 2 diabetes
         Medicine/Public Health
         general
         Biomedicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-43/MediaObjects/12916_2012_Article_704_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-43/MediaObjects/12916_2012_Article_704_Fig2_HTML.jpg
      isPartOf:
         name:BMC Medicine
         issn:
            1741-7015
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Clifford J Bailey
            affiliation:
                  name:Aston University
                  address:
                     name:Life and Health Sciences, Aston University, Birmingham, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jorge L Gross
            affiliation:
                  name:Universidade Federal do Rio Grande do Sul
                  address:
                     name:Endocrine Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Delphine Hennicken
            affiliation:
                  name:Bristol-Myers Squibb, Parc de l'Alliance
                  address:
                     name:Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Braine I'Alleud, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nayyar Iqbal
            affiliation:
                  name:Bristol-Myers Squibb
                  address:
                     name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Traci A Mansfield
            affiliation:
                  name:Bristol-Myers Squibb
                  address:
                     name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James F List
            affiliation:
                  name:Bristol-Myers Squibb
                  address:
                     name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Medicine
      issn:
         1741-7015
      volumeNumber:11
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Aston University
      address:
         name:Life and Health Sciences, Aston University, Birmingham, UK
         type:PostalAddress
      name:Universidade Federal do Rio Grande do Sul
      address:
         name:Endocrine Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
         type:PostalAddress
      name:Bristol-Myers Squibb, Parc de l'Alliance
      address:
         name:Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Braine I'Alleud, Belgium
         type:PostalAddress
      name:Bristol-Myers Squibb
      address:
         name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
         type:PostalAddress
      name:Bristol-Myers Squibb
      address:
         name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
         type:PostalAddress
      name:Bristol-Myers Squibb
      address:
         name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Clifford J Bailey
      affiliation:
            name:Aston University
            address:
               name:Life and Health Sciences, Aston University, Birmingham, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jorge L Gross
      affiliation:
            name:Universidade Federal do Rio Grande do Sul
            address:
               name:Endocrine Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
               type:PostalAddress
            type:Organization
      name:Delphine Hennicken
      affiliation:
            name:Bristol-Myers Squibb, Parc de l'Alliance
            address:
               name:Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Braine I'Alleud, Belgium
               type:PostalAddress
            type:Organization
      name:Nayyar Iqbal
      affiliation:
            name:Bristol-Myers Squibb
            address:
               name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
               type:PostalAddress
            type:Organization
      name:Traci A Mansfield
      affiliation:
            name:Bristol-Myers Squibb
            address:
               name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
               type:PostalAddress
            type:Organization
      name:James F List
      affiliation:
            name:Bristol-Myers Squibb
            address:
               name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Life and Health Sciences, Aston University, Birmingham, UK
      name:Endocrine Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
      name:Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Braine I'Alleud, Belgium
      name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
      name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA
      name:Global Clinical Research, Bristol-Myers Squibb, Princeton, USA

External Links {🔗}(102)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.28s.

LINK . SPRINGER . COM {}